Effects of recombinant human erythropoietin combined with budesonide on inflammatory factors and pulmonary function improvement in premature infants with bronchopulmonary dysplasia
Objective To investigate the effect of recombinant human erythropoietin combined with budesonide on inflammatory factors and pulmonary function improvement in premature infants with bronchopulmonary dysplasia.Methods A total of 116 premature infants with bronchopulmonary dysplasia admitted to our hospital from November 2021 to October 2022 were randomly divided into the control group(58 cases)and the observation group(58 cases).Patients in the control group were treated with budesonide,and those in the observation group were treated with recombinant human erythropoietin combined with budesonide.Inflammatory factors before and after treatment were compared,including the tumor necrosis factor alpha(TNF-α),interleukin 6(IL-6)and IL-8.Pulmonary function before and after treatment were compared,including the respiratory rate(RR),peak inspiratory pressure(PIP)and tidal volume(VT).Blood gas indexes before and after treatment were compared,including the partial pressure of oxygen(PO2),oxygen saturation(SpO2)and partial pressure of carbon dioxide(PCO2).The curative effect and complications of the two groups were compared.Results Before treatment,there were no significant differences in the serum TNF-α,IL-6 and IL-8 levels between groups(P>0.05),which were significantly reduced in the both groups after treatment and the decreases were more pronounced in the observation group than those of the control group(P<0.05).Before treatment,there were no significant differences in the RR,RIP and VT between groups(P>0.05),which were significantly improved in the both groups after treatment and the improvements were more pronounced in the observation group than those of the control group(P<0.05).Before treatment,there were no significant differences in the PO2,SpO2 and PCO2 between groups(P>0.05),which were significantly improved in the both groups after treatment and the improvements were more pronounced in the observation group than those of the control group(P<0.05).The efficacy of the observation group was significantly better than that of the control group,and the incidence of complications was significantly lower(P<0.05).Conclusion The treatment of human recombinant erythropoietin combined with budesonide in premature infants with bronchopulmonary dysplasia can improve their blood gas indexes,reduce the level of inflammation and improve pulmonary function.
recombinant human erythropoietinbudesonidepremature infants with bronchopulmonary dysplasiainflammatory factorspulmonary function
维普
万方数据
